Physician profile
Mark W Stalder
NPI 1558685578
$8,037.30
in general payments reported to CMS, 2019-2025
23 companies · $612 in 2025
The $612 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $705 · 2021: $917 · 2022: $977 · 2023: $1,460 · 2024: $846 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,909 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,908.86 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,297.52 | 2023-2025 | Alloderm, Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps |
| Allergan, INC. | $1,355.45 | 2019-2022 | |
| Mentor Worldwide LLC | $1,173.39 | 2019-2023 | Artoura Breast Tissue Expander, Mentor Memorygel Resterilizable Gel Sizer, Mentor Memorygel Breast Implant |
| Baxter Healthcare | $457.07 | 2019-2023 | Artiss |
| Sientra, INC. | $405.68 | 2019-2022 | |
| Axogen | $381.78 | 2019-2021 | |
| Polarityte, INC. | $369.32 | 2019 | |
| Polynovo North America LLC | $282.72 | 2019-2020 | |
| Sonavex, INC. | $268.24 | 2019-2020 | |
| Musculoskeletal Transplant Foundation INC. | $231.85 | 2019-2022 | |
| Osiris Therapeutics INC. | $212.58 | 2019 | |
| Integra Lifesciences Corporation | $181.45 | 2023-2024 | Durasorb Monofilament Mesh, Integra, Surgimend |
| Stryker Corporation | $100.40 | 2019 | |
| Smith+Nephew, INC. | $86.39 | 2019-2023 | Pico 7 |
| Avanos Medical | $63.71 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $33.44 | 2022-2023 | Dysport |
| Revance Therapeutics, INC. | $25.00 | 2024 | Daxxify |
| Becton, Dickinson and Company | $24.93 | 2024 | Phasix Mesh |
| Bioventus LLC | $20.62 | 2023 | Theragenesis Bilayer Wound Matrix |
| Kci USA, INC. | $18.61 | 2019 | |
| Acera Surgical, INC. | $17.28 | 2019 | |
| Convatec INC. | $15.64 | 2019 | |
| Tactile Systems Technology INC | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stalder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.